MedTrace Logo

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

NCT04513340 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-09-10

No results posted yet for this study

Summary

The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics

Conditions

  • Parkinson Disease

Interventions

DRUG

WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG

Sponsors & Collaborators

  • Hong Kong WD Pharmaceutical Co., Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-13
Primary Completion
2020-09-05
Completion
2021-02-13
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513340 on ClinicalTrials.gov